Vax Before Cancer

 / June 18th, 2021

Eliminating fake vaccine news with pharmacist, nurse, and physician review.

Jun 18 • 9:41 am CDT
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on June 1, 2021, that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory...
Jun 10 • 9:15 pm CDT
California-based AIVITA Biomedical Inc. announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1. The analysis focused on the 57 Phase 2 patients who received eight doses of AV-GBM-1 over approximately...
Jun 9 • 5:34 pm CDT
In a cohort study published by JAMA Oncology on June 4, 2021, of 1,891 Black breast cancer survivors, higher waist-to-hip ratio and body adiposity at approximately 10 months after diagnosis were associated with significantly worse overall...
Jun 9 • 12:44 pm CDT
Idaho-based Therapeutic Solutions International, Inc. reported potent synergy between its tumor blood vessel targeting StemVacs-V iPSC immunotherapy and several classical tumor-specific therapeutic vaccines. In a series of experiments, tumor growth administration of dead tumor cells together...
Jun 1 • 7:26 pm CDT
New Jersey-based Janssen Pharmaceutical Companies announced today that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation (BTD) for teclistamab to treat relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf,...

For more articles, try our search.